Propanc Biopharma, Inc.

Nasdaq:PPCB

Pharmaceutical Preparations·CAMBERWELL, VICTORIA, C3

CEO

Nathanielsz James Andrew

Summary Financials

Revenue

—

Adj. EBITDA

-$1.5M

FY 2025

Net Income

-$1.8M

FY 2025

EPS (Diluted)

-$1420.53

FY 2025

Stock Price

$0.17

+3.2%

2026-03-09

52W Range

$0.16 – $9.36

P/E Ratio

-0.0x

Market Cap

$2.7M

Cash

$2,255

FY 2022

Total Debt

$604,019

FY 2025

Net Debt

$601,764

FY 2025

Enterprise Value

$3.3M

Debt / EBITDA

-0.4x

FY 2025

EV / EBITDA

-2.2x

Employees

—

Revenue

—

Adj. EBITDA

-$1.5M

FY 2025

Net Income

-$1.8M

FY 2025

EPS (Diluted)

-$1420.53

FY 2025

Stock Price

$0.17

+3.2%

2026-03-09

52W Range

$0.16 – $9.36

P/E Ratio

-0.0x

Market Cap

$2.7M

Cash

$2,255

FY 2022

Total Debt

$604,019

FY 2025

Net Debt

$601,764

FY 2025

Enterprise Value

$3.3M

Debt / EBITDA

-0.4x

FY 2025

EV / EBITDA

-2.2x

Employees

—